CAS 910463-68-2

CAS 910463-68-2 corresponds to Semaglutide, a drug used to treat type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists, which work by increasing insulin production and reducing the amount of glucose produced by the liver. A weekly injection of Semaglutide has been shown to be effective in lowering blood sugar levels and reducing the risk of cardiovascular events in people with type 2 diabetes. Its potential use in weight management is also being studied.

Common side effects of Semaglutide include nausea, vomiting, and diarrhea. Semaglutide powder is better for type 2 diabetes. Semaglutide raw powder is a new generation of GLP-1 (glucagon-like peptide-1) analogues. Semaglutide is a long-acting formulation based on the basic structure of Liraglutide that is highly effective in the treatment of type 2 diabetes.

Semaglutide, a novel GLP-1 analogue, is injected subcutaneously once a week; Semaglutide is a long-acting GLP-1 analogue developed by Novo Nordisk and injected once a week under the skin. Compared with Liraglutide, Semaglutide has a longer lipid chain and increased hydrophobicity, but Semaglutide is modified with short chain PEG and greatly increased hydrophilicity. PEG modification can not only bind to albumin closely, cover the hydrolysis site of DPP-4 enzyme, but also reduce renal excretion, prolong biological half-life, and achieve a long cycle effect. Novo Nordisk's Semaglutide is made from DPP-4's sittalliptin and GLP-1's progenitor exenatide. High doses of Semaglutide reduced A1C by 1.6% and body weight by up to 6kg.

A randomized placebo-controlled clinical trial enrolled 3,183 patients with type 2 diabetes. Patients received either sommarutide or placebo daily for an average of 15.9 months.

The incidence of major adverse cardiovascular events was 3.8% in Semaglutide group and 4.8% in placebo group, suggesting that Sommarutide had no significant adverse effects compared with placebo.

Major adverse cardiovascular events included: death from cardiovascular disease, non-fatal myocardial infarction, and non-fatal stroke;

Semaglutide significantly reduced cardiovascular mortality and all-cause mortality, and did not significantly increase the risk of non-fatal myocardial infarction and non-fatal stroke.

Semaglutide was prepared by solid-liquid synthesis method, linear peptide Aib8, Arg34GLP-1(7-37) and aliphatic acylating agent were prepared by solid-phase synthesis method, and linear peptide Lys26 was modified by synthetic aliphatic acylating agent under alkaline conditions to obtain Semaglutide. The bioactivity of the self-made samples was determined by time-resolved fluorescence resonance energy transfer immunoassay.

Hot Tags: cas 910463-68-2, China cas 910463-68-2 manufacturers, suppliers, factory, weight loss liquid peptide, high quality weight loss peptide, professional weight loss peptide, weight loss blend peptide, weight loss stack peptide, Semaglutide-2mg